The regulation of metabolic-related genes, such as SLC25A22, may reverse radiotherapy resistance,81 while PPAR-γ agonists can inhibit tumor progression by regulating the ALDOC-PPAR-γ axis.41 The gene discussed is ALDOC; the disease is neoplasm.